Durham, NCNCT06798909Now EnrollingIRB Ready

Kidney Transplant Clinical Trial in Durham, NC

Access cutting-edge kidney transplant treatment through this phase 3 clinical trial at a research site in Durham. Study-provided care at no cost to qualified participants.

Sponsored by University of California, San Francisco

Quick Self-Assessment

See if you qualify for this Durham location

Preparing your pre-screening questions…

Expert Care in Durham

Access kidney transplant specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related kidney transplant treatment provided free

Apply for This Durham Location

Check if you qualify for this kidney transplant clinical trial in Durham, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Durham

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Durham site if eligible
  4. 4Begin participation

About This Kidney Transplant Study in Durham

This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily \[both dose adjusted per

Sponsor: University of California, San Francisco

Who Can Participate

Inclusion Criteria

Subject or legally authorized representative has provided written informed consent.
Age ≥ 18 years of age at the time of informed consent.
Negative for IgG antibody to CMV as assessed in a CLIA-certified laboratory between 28 days prior to transplant and up to 7 days post-transplant but prior to randomization.
Received a kidney transplant from a CMV seropositive (IgG positive) donor in the past 7 days prior to enrollment
Individuals of reproductive (childbearing) potential must have a negative pregnancy test (serum or urine) collected prior to randomization (SOC results within 7 days prior to transplant may be used), and must also agree to use a medically approved method of contraception. Acceptable methods include: barrier method, intrauterine device (hormonal or non-hormonal), oral hormonal contraceptives, abstinence from the time of enrollment through until discontinuation of ganciclovir or valganciclovir in either arm during the intervention period. NOTE: Individuals of reproductive potential are defined as individuals who have reached menarche and who have not been post-menopausal for at least 12 consecutive months with follicle stimulating hormone (FSH) ≥40 IU/mL or 24 consecutive months if an FSH is not available, i.e., who have had menses within the preceding 24 months, and have not undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, or salpingectomy).
If male, must agree to practice a barrier method of contraception or abstinence from the time of enrollment through 3 months after discontinuation of ganciclovir or valganciclovir in either arm during the intervention period.

Exclusion Criteria

In the opinion of the investigator, participants who are unable or unwilling to undergo preemptive therapy protocol (weekly CMV PCR, etc.)
Patients who are breastfeeding or planning to breastfeed within 6 months post-transplant
Allergy to valganciclovir/ganciclovir or Letermovir
Receipt of immunoglobulin or CMV-specific immunoglobulin within the last 3 months (this includes COVID convalescent plasma)
Currently enrolled or anticipated enrollment in another interventional study that, in the opinion of scientific leadership team, could affect evaluation of the primary safety and/or efficacy outcomes.
Most recent platelet count post-transplant \<25,000/uL
Most recent ANC performed post-transplant \<1000/uL
Multi-organ transplant (except simultaneous kidney-pancreas) within the past 7 days
Prior or planned receipt of a hematopoietic cell transplant
Baseline immunodeficiency prior to transplant, including but not limited to:
Known or suspected HIV infection
Congenital or acquired immunodeficiency
Unacceptable immunosuppression
Receipt of desensitization therapy prior to kidney transplant, or
Receipt of an ABO-incompatible kidney transplant except A2 to blood type B

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Durham?

Yes, this clinical trial (NCT06798909) has an active research site in Durham, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Kidney Transplant Treatment Options in Durham, NC

If you're searching for kidney transplant treatment options in Durham, NC, this clinical trial (NCT06798909) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Durham research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced kidney transplant specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all kidney transplant clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Durham, NC

See all rheumatoid arthritis clinical trials recruiting in Durham — not just this study.

Browse Rheumatoid Arthritis Trials in Durham →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAll Conditions →

Ready to Join in Durham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Durham, NC